ViroPharma is a biotechnology company. Co. markets and sells Cinryze in the U.S. for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Co. also sells branded and authorized generic Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is indicated for the treatment of C. difficile-associated diarrhea (CDAD). Co.'s product development portfolio is primarily focused on these programs: C1 esterase inhibitor [human]; maribavir for cytomegalovirus infection; VP20621 for prevention of recurrent CDAD; and VP20629 for treatment of Friedreich's Ataxia.